Compare Nutrien Ltd (NTR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Nutrien Ltd trades at $67.23 (market cap $33.31B), while Regeneron Pharmaceuticals Inc trades at $745.87 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.3× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| NTR | REGN | |
|---|---|---|
Market Cap | $33.31B | $76.14B |
Volume | 1,330,729 | 500,239 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $852.03 |
52-Week Low | $53.64 | $557.73 |
Typical Hold Time | 59 Days | 107 Days |
Enterprise Value | $45.11B | $70.85B |
Dividend Yield | 3.15% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $68.29, down 2.4% today, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation metrics with P/E of 14.14 and P/S of 1.2, while profitability metrics include 8.44% net margin and 9.34% ROE. Recent news highlights industry headwinds from potential Belarus potash imports and an upcoming Investor Day in November 2026.
The outlook remains cautiously optimistic with 60.6% analyst buy ratings and a $76.14 consensus target, though risks include fertilizer price volatility and competitive pressures. Cash flow trends show consistent operational strength but negative net flows in recent years, requiring careful monitoring of debt levels and agricultural market cycles.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
